Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 21, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Presentation at the reimagine Health Research Symposium Features Overview of Platform Technology and Four Antiviral Case Studies

BOTHELL, Wash., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
January 19, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement

Program advances within the agreement’s initial two-year timeframe BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a...
January 14, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal to Present at the 3rd Annual reimagine Health Research Symposium

BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
January 12, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at Virtual NobleCon17 Conference on January 19, 2021

BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
January 05, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
December 22, 2020 08:30 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses

CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2 BOTHELL, Wash., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cocrystal...
November 16, 2020 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end...
November 10, 2020 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Selected to Present at the World Antiviral Conference

BOTHELL, WA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
November 06, 2020 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference

– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST – BOTHELL, WA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP),...
October 19, 2020 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Provides Update on Influenza A Program

– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for...